News Release

Malaria research article cites use of HemogloBind^TM in reticulocyte study

MONMOUTH JUNCTION, NJ, September 18, 2020 -- Biotech Support Group reports on a journal article describing the efficiency and simplicity of hemoglobin depletion products for Western blot analysis of reticulocytes (Retics) lysates.

The citation is:

Hojo-Souza NS, de Azevedo PO, de Castro JT, Teixeira-Carvalho A, Lieberman J, et al. (2020) Contributions of IFN-γ and granulysin to the clearance of Plasmodium yoelii blood stage. PLOS Pathogens 16(9): e1008840. https://doi.org/10.1371/journal.ppat.1008840

The authors describe how P. vivax-infected Retics (iRetics) express human leukocyte antigen class I (HLA-I), which are recognized by CD8+ T cells and killed by granulysin (GNLY) and granzymes. However, how Plasmodium infection induces MHC-I expression on Retics is unknown. In addition, whether GNLY helps control Plasmodium infection in vivo has not been studied. To remove interferences associated with Hemoglobin, the article states, “For western blot analysis, erythroblasts pellets were resuspended in RIPA Buffer (Sigma)…. The Retics were treated with HemogloBind (Biotech Support Group) …”. The research results indicate that in addition to previously described mechanisms, IFN-γ promotes host resistance to the Retic-tropic P. yoelii 17XNL strain by promoting MHC-I expression on iRetics that become targets for CD8+ cytotoxic T lymphocytes and GNLY.

“I am pleased to see another use for HemogloBind^TM in malaria research of reticulocytes. With the efficiency of Hemoglobin removal that our products provide, investigators can now study the many aspects of red cells as they relate to disease. Finally, we can provide a simple method to remove Hemoglobin interference, as this can often be a problem with immunoassay and Western blot analysis. Furthermore, this article demonstrates compatibility with the commonly used RIPA lysis buffer.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For Business Development, Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com